a Laboratory of Molecular Biology , Federal State Budgetary Institution "Research Centre for Medical Genetics" , Moscow , Russia.
b Department of Neurology, Neurosurgery and Medical Genetics , Pirogov Russian National Research Medical University , Moscow , Russia.
Crit Rev Clin Lab Sci. 2018 Jan;55(1):55-70. doi: 10.1080/10408363.2017.1420032. Epub 2018 Jan 5.
There is currently no proposed stroke biomarker with consistent application in clinical practice. A number of studies have examined cell-free DNA (cfDNA), which circulates in biological fluids during stroke, as a potential biomarker of this disease. The data available suggest that dynamically-determined levels of blood cfDNA may provide new prognostic information for assessment of stroke severity and outcome. However, such an approach has its own difficulties and limitations. This review covers the potential role of cfDNA as a biomarker in stroke, and includes evidence from both animal models and clinical studies, protocols used to analyze cfDNA, and hypotheses on the origin of cfDNA.
目前，临床上还没有一种一致应用的中风生物标志物。一些研究已经检查了游离细胞 DNA（cfDNA），它在中风期间在生物体液中循环，作为这种疾病的潜在生物标志物。现有的数据表明，血液 cfDNA 的动态变化水平可能为评估中风严重程度和结果提供新的预后信息。然而，这种方法有其自身的困难和局限性。这篇综述涵盖了 cfDNA 作为中风生物标志物的潜在作用，包括来自动物模型和临床研究的证据、用于分析 cfDNA 的方案以及对 cfDNA 起源的假设。
